Search Within

Zachary Drew Epstein-Peterson

Formats
  1. Meeting Abstract (56)
  2. Journal Article (21)
  3. Review (9)
  4. Research Letter (7)
  5. Editorial (1)
Groups
  1. Hematologic Malignancies, Division of (94)
  2. Hematology-Oncology Fellows (94)
  3. Department of Medicine (90)
  4. Center for Hematologic Malignancies (89)
  5. Lymphoma (69)
  6. Population Sciences Research Program (54)

More Groups

People
  1. Steven Horwitz (47)
  2. Alison Moskowitz (45)
  3. Anita Kumar (43)
  4. Gilles Salles (38)
  5. Maria Palomba (38)
  6. Andrew Zelenetz (35)

More People

Years
  1. 2025 (8)
  2. 2024 (23)
  3. 2023 (24)
  4. 2022 (10)
  5. 2021 (8)
  6. 2020 (7)

More Years

Publications
  1. Blood (49)
  2. Blood Advances (5)
  3. Haematologica (5)
  4. Hematological Oncology (4)
  5. Leukemia Research (4)
  6. American Journal of Hematology (3)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. Wiley Blackwell (6)
  3. Ferrata Storti Foundation (5)
  4. Elsevier Ltd (4)
  5. Nature Publishing Group (4)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (94)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
    Meeting Abstract

    Shastri, A.; Feldman, E. J.; Starodub, A. N.; Feldman, T.; Rodriguez, C. P.; Epstein-Peterson, Z. D.; Stevens, D. A.; Olszewski, A. J.; Huen, A. O.; Porcu, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cutaneous T-cell lymphoma and dupilumab use: A retrospective matched cohort study of clinical characteristics and treatment outcomes
    Meeting Abstract

    Stuver, R.; Dusza, S.; Epstein-Peterson, Z. D.; Ghione, P.; Johnson, W.; Moskowitz, A.; Myskowski, P.; Pulitzer, M.; Horwitz, S. M.; Geller, S.
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cumulative incidence of myeloid neoplasms in patients with nodal T-follicular helper cell lymphoma
    Meeting Abstract

    Stuver, R.; Ganesan, N.; Dogan, A.; Epstein-Peterson, Z. D.; Ghione, P.; Johnson, W.; Lewis, N.; Moskowitz, A.; Shah, G. L.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
    Blood (2023)

    Fulltext@MSK | Save